Integrated Safety Analysis of Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor, in Relapsed/Refractory Lymphoid Malignancies By admin / 09/21/2021
Long term Results of a Phase I/ Ib Study of Ibrutinib in Combination with Umbralisib in Patients with Relapsed/Refractory CLL or MCL By admin / 06/12/2020
Umbralisib in Combination with Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia or Mantle Cell Lymphoma: A Multicentre Phase 1–1b Study By admin / 12/14/2018
Long Term Integrated Safety Analysis Of Umbralisib (TGR-1202), A PI3K?/Ck1? Inhibitor With A Differentiated Safety Profile, In Patients With Relapsed/Refractory Lymphoid Malignancies By admin / 06/15/2018
An Integrated Safety Analysis of the Next Generation PI3K Delta Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies By admin / 12/11/2017
Updated Results of a Multicenter Phase I/IB Study of Umbralisib (TGR-1202) in Combination with Ibrutinib in Patients with Relapsed or Refractory MCL or CLL By admin / 06/14/2017
TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL: Updated Results of a Multicenter Phase I/Ib Study By admin / 05/15/2017
TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. By admin / 12/05/2016
Preliminary Results of a Phase I/Ib Study of Ibrutinib in Combination with TGR-1202 in Patients with Relapsed/Refractory CLL or MCL. By admin / 06/01/2016
